BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15621815)

  • 21. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
    Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
    Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab).
    Nakagawa Y; Ikeda U; Hirose M; Ubukata S; Katsuki TA; Kaminishi Y; Saito T; Hironaka M; Izumi T; Shimada K
    Circ J; 2004 Feb; 68(2):172-3. PubMed ID: 14745155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab].
    Kataoka T; Ishida Y; Kurokawa R; Takeshita S; Ohta K; Nishimura Y; Yokoyama M
    Nihon Kokyuki Gakkai Zasshi; 2003 Dec; 41(12):899-904. PubMed ID: 14727553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravascular lymphoma: a role for single-agent rituximab.
    Bazhenova L; Higginbottom P; Mason J
    Leuk Lymphoma; 2006 Feb; 47(2):337-41. PubMed ID: 16321868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Follicular lymphoma: 2012 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
    Robak T; Smolewski P; Urbanska-Rys H; Gora-Tybor J; Blonski JZ; Kasznicki M
    Leuk Lymphoma; 2004 May; 45(5):937-44. PubMed ID: 15291352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection.
    Spina M; Sparano JA; Jaeger U; Rossi G; Tirelli U
    AIDS; 2003 Jan; 17(1):137-8. PubMed ID: 12478085
    [No Abstract]   [Full Text] [Related]  

  • 33. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
    Keilholz U; Szelényi H; Siehl J; Foss HD; Knauf W; Thiel E
    Leuk Lymphoma; 1999 Nov; 35(5-6):641-2. PubMed ID: 10609806
    [No Abstract]   [Full Text] [Related]  

  • 35. Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen--diagnostic and therapeutic dilemmas.
    Robak T; Urbańska-Ryś H; Jerzmanowski P; Bartkowiak J; Liberski P; Kordek R
    Leuk Lymphoma; 2002 Dec; 43(12):2343-50. PubMed ID: 12613522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD20 role in pathophysiology of Hodgkin's disease.
    Santos MAO; Lima MM
    Rev Assoc Med Bras (1992); 2017 Sep; 63(9):810-813. PubMed ID: 29239464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma.
    Gao G; Liang X; Jiang J; Zhou X; Huang R; Chu Z; Zhan Q
    Acta Oncol; 2010; 49(1):3-12. PubMed ID: 19714523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
    Palickova M; Mocikova H; Vernerova Z; Campr V; Kozak T
    Leuk Lymphoma; 2013 Sep; 54(9):2081-2. PubMed ID: 23311295
    [No Abstract]   [Full Text] [Related]  

  • 39. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastric non-Hodgkin's lymphoma after successful treatment of Hodgkin's disease.
    Eridani S; Singh AK
    Oncology; 1986; 43(2):107-9. PubMed ID: 3754040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.